Effectiveness and Safety of Albuterol Solutions With and Without Benzalkonium Chloride

Abstract

INTRODUCTION: Continuous aerosolized β2 agonist, namely albuterol, is the most commonly used therapy for critical asthma. Benzalkonium chloride is a preservative present in some for-mulations of aerosolized albuterol solutions that can induce bronchospasm. Recent studies have shown that inhalation of albuterol containing benzalkonium chloride might induce unintended bronchoconstriction and poor outcomes. This study aimed to investigate whether using albuterol solutions containing benzalkonium chloride results in prolonged hospital length of stay (LOS). METHODS: This was a retrospective cohort study of pediatric subjects admitted to the pediatric ICU (PICU) and treated with continuous albuterol. Data were collected and compared before and after a change to benzalkonium chloride–containing solutions. Subjects who were treated with preservative-free solutions were used as control. The primary outcome was PICU and hospital LOS; secondary outcomes included the duration of continuous albuterol and use of adjunctive therapies. RESULTS: A total of 266 admissions were included in the study. One hundred forty subjects (52.6%) were exposed to benzalkonium chloride. Median age and severity of illness scoring were similar between groups. The initial dose of continuous albuterol was signifi-cantly higher in the benzalkonium chloride group (median 15 interquartile range [IQR] 10–20 mg/h) compared to the preservative-free group (median 10 IQR 10–20 mg/h) (P < .001). PICU LOS was longer for the preservative-free group, 2.5 (IQR 1.4–4.6) d vs 1.8 (IQR 1.1–2.9) d for benzalkonium chloride group (P 5 .002). There was no significant difference in duration of continuous albuterol therapy (P 5 .16) or need for adjunctive respiratory support (heliox [P 5 .32], noninvasive ventilation [P 5 .81], and invasive mechanical ventilation [P 5 .57]). CONCLUSIONS: In contrast to published literature showing that benzalkonium chloride may be associated with a longer duration of continuous albuterol nebulization and hospital LOS, our study demonstrated that benzalkonium chloride–containing albuterol is safe for continuous neb-ulization in critically ill children and not associated with worse outcomes.